On November 10, Madrigal Pharmaceuticals rose 7.31% in Regular Trading, trading at $429.2 per share, with turnover of $86.07 million.
The move followed new AASLD data showing that, in real-world studies, up to 93% of patients treated with Rezdiffra experienced improvement or stabilization in liver stiffness on ultrasound elastography, with many shifting into lower liver stiffness categories, alongside improvements in cardiometabolic health markers.
Recent supporting context has also been constructive: the company reported third-quarter EPS of $1.83 and revenue of $431.268 million, both above consensus, ended the quarter with $961.8 million in cash and investments, and received a price-target increase to $743 from $709 while maintaining a Buy rating.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments